Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 3/20 | 0.52 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.41 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL949286 | 0.88 | HPGDS (0.49) | HPGDSGPR119 | |
| SCHEMBL27201472 | 0.83 | HDAC4 (0.48) | USP30PDE2A | |
| SCHEMBL23130932 | 0.82 | F10 (0.44) | HPGDSUSP30GPR119KCNK3KCNK9 | |
| SCHEMBL27201524 | 0.82 | ROCK2 (0.42) | HPGDSUSP30GPR119KCNK3KCNK9 | |
| SCHEMBL27201557 | 0.82 | MAPK1 (0.42) | HPGDSUSP30GPR119KCNK3KCNK9 | |
| SCHEMBL30879863 | 0.82 | HPGDS (0.55) | HPGDSPRMT5JAK2JAK1USP30 | |
| SCHEMBL30879912 | 0.82 | HPGDS (0.55) | HPGDSPRMT5JAK2JAK1USP30 | |
| SCHEMBL30879914 | 0.82 | HPGDS (0.55) | HPGDSPRMT5JAK2JAK1USP30 | |
| SCHEMBL27201443 | 0.81 | MALT1 (0.41) | HPGDSUSP30GPR119KCNK3KCNK9 | |
| SCHEMBL19385367 | 0.81 | USP30 (0.57) | HPGDSUSP30GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2024073502-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | GID4, MDM2, XIAP | HPGDS 1284/4885PRMT5 2343/4885JAK2 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.